|
![]() |
|
|
Ipratropium_Bromide: profile and news
Nebulizer-Associated Anisocoria Mar 1, 2006 James Le Fanu investigates some pillow ploys for runny noses Jan 9, 2006 Breathe Easier! Jan 22, 2006 No Justification for Deep Cut in 2006 Medicare Dispensing Fee for ... Nov 13, 2005 Diagnosing Airway Disease Dec 2, 2005 Asthma and COPD Patients Find New Soft Mist Inhaler Highly ... Sep 19, 2005 44% of Homecare Pharmacies Will Stop Providing Inhalation Drug ... Oct 3, 2005 Head-to-Head Study Shows COPD Patients Achieve Significantly ... Sep 18, 2005 Head-to-head Study Shows COPD Patients Achieve Significantly ... Sep 19, 2005 American Association for Homecare Opposes Any Cut to Dispensing ... 06 Aug 2005 Photo: Edwina Pickles Jul 6, 2005 Drug Company Settles Price-Fixing Case in Connecticut Jul 20, 2005 Photo: Edwina Pickles Jul 6, 2005 Changes in Inhaler Devices for Asthma And COPD Jun 19, 2005 Ignorance of doctors is risking lives Jun 24, 2005 Ignorance of doctors is risking lives Jun 24, 2005 Changes in Inhaler Devices for Asthma And COPD Jun 19, 2005 Chronic Obstructive Pulmonary Disease Jun 8, 2005 DATAMONITOR: Novel Combinations Breathe Life into COPD Market Apr 26, 2005 Boehringer Ingelheim reports strong 2004 Apr 7, 2005 Texas Goes After Big Pharma Mar 4, 2005 Other information Indication For maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema Pharmacology Ipratropium bromide, a synthetic ammonium compound structurally similar to atropine, is used as a bronchodilator in the management of cholinergic-mediated bronchospasm associated with chronic obstructive pulmonary disease and in the treatment of rhinorrhea associated with the common cold or with allergic or nonallergic seasonal rhinitis. Mechanism Of Action Ipratropium bromide is an anticholinergic agent. It blocks muscarinic cholinergic receptors, without specificity for subtypes, resulting in a decrease in the formation of cyclic guanosine monophosphate (cGMP). Most likely due to actions of cGMP on intracellular calcium, this results in decreased contractility of smooth muscle. Drug Category Bronchodilator Agents; Cholinergic Antagonists; Antimuscarinics; Antispasmodics; ATC:R01AX03; ATC:R03BB01 Brand Names/Synonyms Aerovent; Apo-Ipravent; Apovent; Atronase; Atrovent; Atrovent Aerosol; Atrovent Hfa; Atrovent Nasal; Bitrop; Disne-Asmol; IPRATROPIUM; Ipatropium Bromide; Ipratropium; Ipratropium Bromide; Ipravent; Ipvent; Kendral-Ipratropium; N-Isopropylatropine; Narilet; Rhinotrop; Rhinovent; Rinatec; Rinoberen; Rinovagos; Vagos Dosage Forms AEROSOL (WITH PROPELLANTS); LIQUID; METERED-DOSE (AEROSOL); METERED-DOSE (PUMP); SOLUTION Absorption Inhalation (local)-minimal; Nasal-rapid and minimal Interactions Interactions for Ipratropium: ATROVENT Inhalation Aerosol has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, and steroids, commonly used in the treatment of chronic obstructive pulmonary disease. With the exception of albuterol, there are no formal studies fully evaluating the interaction effects of ATROVENT Inhalation Aerosol and these drugs with respect to effectiveness. Anticholinergic agents: Although ipratropium bromide is minimally absorbed into the systemic circulation, there is some potential for an additive interaction with concomitantly used anticholinergic medications. Caution is therefore advised in the coadministration of ATROVENT Inhalation Aerosol with other anticholinergic-containing drugs. Chemical IUPAC Name [8-methyl-8-(1-methylethyl)-8-azoniabicyclo[3.2.1]oct-3-yl]3-hydroxy-2-phenyl-propanoate Chemical Formula C20H30NO3 Half Life ~2 hours Drug Type Approved Drug # Accession No APRD00537 CAS Registry Number 60205-81-4 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |